Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention

References

• Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803–1820. doi:10.1016/S0140-6736(22)01655-5
   PubMed Web of Science ®Google Scholar
• Quattrin T, Mastrandrea LD, Walker LSK. Type 1 diabetes. Lancet. 2023;401(10394):2149–2162. doi:10.1016/S0140-6736(23)00223-4
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Lamartina L, Leboulleux S, Borget I, Schlumberger M. Global thyroid estimates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):235–236. doi:10.1016/S2213-8587(22)00048-1
   PubMed Web of Science ®Google Scholar
• Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401(10387):1531–1544. doi:10.1016/S0140-6736(23)00020-X
   PubMed Web of Science ®Google Scholar
• Greenwood M, Wood F. The relation between the cancer and diabetes death-rates. J Hyg. 1914;14(1):83–118. doi:10.1017/S0022172400005702
   PubMedGoogle Scholar
• Popovic K, Smolovic B, Martinovic M, Vuckovic L. The relationship between diabetes mellitus and pancreatic cancer-diabetes mellitus as a red flag for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2023;32(3):298–305. doi:10.1158/1055-9965.EPI-22-0951
   PubMed Web of Science ®Google Scholar
• Guo J, Liu C, Pan J, Yang J. Relationship between diabetes and risk of gastric cancer: a systematic review and meta-analysis of cohort studies. Diabet Res Clin Pract. 2022;187:109866. doi:10.1016/j.diabres.2022.109866
   PubMed Web of Science ®Google Scholar
• Sun X, Zhang Q, Kadier K, et al. Association between diabetes status and breast cancer in US adults: findings from the US National Health and Nutrition Examination Survey. Front Endocrinol. 2023;14:1059303. doi:10.3389/fendo.2023.1059303
   PubMed Web of Science ®Google Scholar
• Khoa Ta HD, Nguyen NN, Ho DKN, et al. Association of diabetes mellitus with early-onset colorectal cancer: a systematic review and meta-analysis of 19 studies including 10 million individuals and 30,000 events. Diabetes Metab Syndr. 2023;17(8):102828. doi:10.1016/j.dsx.2023.102828
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid. 2011;21(9):957–963. doi:10.1089/thy.2010.0396
   PubMed Web of Science ®Google Scholar
• Linkeviciute-Ulinskiene D, Patasius A, Zabuliene L, Stukas R, Smailyte G. Increased risk of site-specific cancer in people with type 2 diabetes: a National Cohort Study. Int J Environ Res Public Health. 2019;17(1):246. doi:10.3390/ijerph17010246
   PubMed Web of Science ®Google Scholar
• Yeo Y, Ma SH, Hwang Y, et al. Diabetes mellitus and risk of thyroid cancer: a meta-analysis. PLoS One. 2014;9(6):e98135. doi:10.1371/journal.pone.0098135
   PubMed Web of Science ®Google Scholar
• Zhan YS, Feng L, Tang SH, et al. Glucose metabolism disorders in cancer patients in a Chinese population. Med Oncol. 2010;27(2):177–184. doi:10.1007/s12032-009-9189-9
   PubMed Web of Science ®Google Scholar
• Yin DT, He H, Yu K, et al. The association between thyroid cancer and insulin resistance, metabolic syndrome and its components: a systematic review and meta-analysis. Int J Surg. 2018;57:66–75. doi:10.1016/j.ijsu.2018.07.013
   PubMed Web of Science ®Google Scholar
• Seo YG, Choi HC, An AR, et al. The Association between Type 2 Diabetes Mellitus and Thyroid Cancer. J Diabetes Res. 2017;2017:5850879. doi:10.1155/2017/5850879
   PubMedGoogle Scholar
• Carstensen B, Read SH, Friis S, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9000 cancers in type 1 diabetic individuals. Diabetologia. 2016;59(5):980–988. doi:10.1007/s00125-016-3884-9
   PubMed Web of Science ®Google Scholar
• Li H, Qian J. Association of diabetes mellitus with thyroid cancer risk: a meta-analysis of cohort studies. Medicine. 2017;96(47):e8230.
   PubMed Web of Science ®Google Scholar
• Dong WW, Zhang DL, Wang ZH, Lv CZ, Zhang P, Zhang H. Different types of diabetes mellitus and risk of thyroid cancer: a meta-analysis of cohort studies. Front Endocrinol. 2022;13:971213. doi:10.3389/fendo.2022.971213
   PubMedGoogle Scholar
• Saewai C, Fumaneeshoat O, Thongsuksai P, Ingviya T. Diabetes mellitus as cancer risk: a 14-year, cross-sectional analysis. Nutr Cancer. 2023;75(6):1454–1463. doi:10.1080/01635581.2023.2205054
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang X, Ma Y, et al. Incident type 2 diabetes duration and cancer risk: a prospective study in two US cohorts. J Natl Cancer Inst. 2021;113(4):381–389. doi:10.1093/jnci/djaa141
   PubMedGoogle Scholar
• Bezin J, Gouverneur A, Penichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384–390. doi:10.2337/dc22-1148
   PubMed Web of Science ®Google Scholar
• Cadenas S. Mitochondrial uncoupling, ROS generation and cardioprotection. Biochim Biophys Acta Bioenergy. 2018;1859(9):940–950. doi:10.1016/j.bbabio.2018.05.019
   PubMed Web of Science ®Google Scholar
• Kunji ERS, King MS, Ruprecht JJ, Thangaratnarajah C. The SLC25 carrier family: important transport proteins in mitochondrial physiology and pathology. Physiology. 2020;35(5):302–327. doi:10.1152/physiol.00009.2020
   PubMed Web of Science ®Google Scholar
• Huang R, Cai T, Zhou Y, et al. Ethnicity differences in the association of UCP1-3826A/G, UCP2-866G/A and Ala55Val, and UCP3-55C/T polymorphisms with type 2 diabetes mellitus susceptibility: an updated meta-analysis. Biomed Res Int. 2021;2021:3482879. doi:10.1155/2021/3482879
   PubMed Web of Science ®Google Scholar
• Zhou M, He S, Ping F, et al. Uncoupling protein 2 and peroxisome proliferator-activated receptor gamma gene polymorphisms in association with diabetes susceptibility in Chinese Han Population with Variant Glucose Tolerance. Int J Endocrinol. 2018;2018:4636783. doi:10.1155/2018/4636783
   PubMed Web of Science ®Google Scholar
• Zhou TC, Yang L, Liu YY, et al. Polymorphisms in the uncoupling protein 2 gene are associated with diabetic retinopathy in Han Chinese Patients with type 2 diabetes. Genet Test Mol Biomarkers. 2018;22(11):637–643. doi:10.1089/gtmb.2018.0115
   PubMed Web of Science ®Google Scholar
• Marques D, Ferreira-Costa LR, Ferreira-Costa LL, et al. Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features. World J Gastroenterol. 2017;23(37):6854–6867. doi:10.3748/wjg.v23.i37.6854
   PubMed Web of Science ®Google Scholar
• Seshadri N, Jonasson ME, Hunt KL, et al. Uncoupling protein 2 regulates daily rhythms of insulin secretion capacity in MIN6 cells and isolated islets from male mice. Mol Metab. 2017;6(7):760–769. doi:10.1016/j.molmet.2017.04.008
   PubMed Web of Science ®Google Scholar
• Din I, Majid S, Rashid F, et al. Mitochondrial uncoupling protein 2 (UCP2) gene polymorphism - 866 G/A in the promoter region is associated with type 2 diabetes mellitus among Kashmiri population of Northern India. Mol Biol Rep. 2023;50(1):475–483. doi:10.1007/s11033-022-08055-z
   PubMed Web of Science ®Google Scholar
• Li W, Zhang C, Jackson K, et al. UCP2 knockout suppresses mouse skin carcinogenesis. Cancer Prev Res. 2015;8(6):487–491. doi:10.1158/1940-6207.CAPR-14-0297-T
   PubMed Web of Science ®Google Scholar
• Yu G, Wang J, Xu K, Dong J. Dynamic regulation of uncoupling protein 2 expression by microRNA-214 in hepatocellular carcinoma. Biosci Rep. 2016;36(3). doi:10.1042/BSR20160062
   Google Scholar
• Hua J, Zhang Z, Zhang L, Sun Y, Yuan Y. UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells. Cancer Chemother Pharmacol. 2021;88(4):633–642. doi:10.1007/s00280-021-04303-4
   PubMed Web of Science ®Google Scholar
• Hima S, Sreeja S. Regulatory role of estrogen-induced reactive oxygen species in the modulatory function of UCP 2 in papillary thyroid cancer cells. IUBMB Life. 2015;67(11):837–846. doi:10.1002/iub.1440
   PubMed Web of Science ®Google Scholar
• Li J, Jiang R, Cong X, Zhao Y. UCP2 gene polymorphisms in obesity and diabetes, and the role of UCP2 in cancer. FEBS Lett. 2019;593(18):2525–2534. doi:10.1002/1873-3468.13546
   PubMed Web of Science ®Google Scholar
• Woyda-Ploszczyca AM, Jarmuszkiewicz W. The conserved regulation of mitochondrial uncoupling proteins: from unicellular eukaryotes to mammals. Biochim Biophys Acta Bioenergy. 2017;1858(1):21–33. doi:10.1016/j.bbabio.2016.10.003
   PubMed Web of Science ®Google Scholar
• Song YS, Kim MJ, Sun HJ, et al. Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth. Clin Cancer Res. 2019;25(1):414–425. doi:10.1158/1078-0432.CCR-18-0663
   PubMed Web of Science ®Google Scholar
• Cho JH, Kim HJ, Lee JH, et al. Poor glycemic control is associated with the risk of subclinical hypothyroidism in patients with type 2 diabetes mellitus. Korean J Intern Med. 2016;31(4):703–711. doi:10.3904/kjim.2015.198
   PubMed Web of Science ®Google Scholar
• Adhami M, Michail P, Rao A, et al. Anti-Thyroid Antibodies and TSH as potential markers of thyroid carcinoma and aggressive behavior in patients with indeterminate fine-needle aspiration cytology. World J Surg. 2020;44(2):363–370. doi:10.1007/s00268-019-05153-1
   PubMed Web of Science ®Google Scholar
• Schiffmann L, Kostev K, Kalder M. Association between various thyroid gland diseases, TSH values and thyroid cancer: a case-control study. J Cancer Res Clin Oncol. 2020;146(11):2989–2994. doi:10.1007/s00432-020-03283-x
   PubMed Web of Science ®Google Scholar
• Zou M, Baitei EY, Al-Rijjal RA, et al. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. Oncogene. 2016;35(15):1909–1918. doi:10.1038/onc.2015.253
   PubMed Web of Science ®Google Scholar
• Papaleontiou M, Chen DW, Banerjee M, et al. Thyrotropin suppression for papillary thyroid cancer: a Physician Survey Study. Thyroid. 2021;31(9):1383–1390. doi:10.1089/thy.2021.0033
   PubMed Web of Science ®Google Scholar
• Hasnain SZ, Borg DJ, Harcourt BE, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014;20(12):1417–1426. doi:10.1038/nm.3705
   PubMed Web of Science ®Google Scholar
• Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of oxidative stress in metabolic syndrome. Int J Mol Sci. 2023;24(9):7898. doi:10.3390/ijms24097898
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxid Med Cell Longev. 2020;2020:8609213. doi:10.1155/2020/8609213
   PubMed Web of Science ®Google Scholar
• Thonsri U, Wongkham S, Wongkham C, et al. High glucose-ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8. Cancer Sci. 2021;112(1):254–264. doi:10.1111/cas.14719
   PubMed Web of Science ®Google Scholar
• Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers. 2019;11(9):1402. doi:10.3390/cancers11091402
   PubMed Web of Science ®Google Scholar
• Maradagi T, Kumar R, Ponesakki G. Hyperglycaemia-induced human hepatocellular carcinoma (HepG2) cell proliferation through ROS-mediated P38 activation is effectively inhibited by a xanthophyll carotenoid, lutein. Diabet Med. 2022;39(2):e14713. doi:10.1111/dme.14713
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42–50. doi:10.1200/JCO.2014.56.8253
   PubMed Web of Science ®Google Scholar
• Wieczorek-Szukala K, Kopczynski J, Kowalska A, Lewinski A. Snail-1 overexpression correlates with metastatic phenotype in BRAF(V600E) positive papillary thyroid carcinoma. J Clin Med. 2020;9(9):2701. doi:10.3390/jcm9092701
   PubMed Web of Science ®Google Scholar
• Han PA, Kim HS, Cho S, et al. Association of BRAF V600E mutation and MicroRNA expression with central lymph node metastases in papillary thyroid cancer: a prospective study from four endocrine surgery centers. Thyroid. 2016;26(4):532–542. doi:10.1089/thy.2015.0378
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu T, Qin W, et al. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer. Biochem Biophys Res Commun. 2020;522(1):21–25. doi:10.1016/j.bbrc.2019.11.047
   PubMed Web of Science ®Google Scholar
• Tabur S, Aksoy SN, Korkmaz H, Ozkaya M, Aksoy N, Akarsu E. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma. Tumour Biol. 2015;36(4):2667–2674. doi:10.1007/s13277-014-2889-6
   PubMedGoogle Scholar
• Ziros PG, Manolakou SD, Habeos IG, et al. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells. J Clin Endocrinol Metab. 2013;98(8):E1422–E1427. doi:10.1210/jc.2013-1510
   PubMed Web of Science ®Google Scholar
• Manzella L, Massimino M, Stella S, et al. Activation of the IGF axis in thyroid cancer: implications for tumorigenesis and treatment. Int J Mol Sci. 2019;20(13):3258. doi:10.3390/ijms20133258
   PubMed Web of Science ®Google Scholar
• Miller BS, Rogol AD, Rosenfeld RG. The history of the insulin-like growth factor system. Horm Res Paediatr. 2022;95(6):619–630. doi:10.1159/000527123
   PubMed Web of Science ®Google Scholar
• Cheng HC, Chang TK, Su WC, Tsai HL, Wang JY. Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. Transl Oncol. 2021;14(7):101089. doi:10.1016/j.tranon.2021.101089
   PubMed Web of Science ®Google Scholar
• Morrione A, Belfiore A. Obesity, diabetes, and cancer: the role of the Insulin/IGF axis; mechanisms and clinical implications. Biomolecules. 2022;12(5):612. doi:10.3390/biom12050612
   PubMed Web of Science ®Google Scholar
• Deleu S, Pirson I, Coulonval K, et al. IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. Mol Cell Endocrinol. 1999;149(1–2):41–51. doi:10.1016/S0303-7207(99)00005-2
   PubMed Web of Science ®Google Scholar
• Wang K, Yang Y, Wu Y, et al. The association between insulin resistance and vascularization of thyroid nodules. J Clin Endocrinol Metab. 2015;100(1):184–192. doi:10.1210/jc.2014-2723
   PubMed Web of Science ®Google Scholar
• Heidari Z, Mashhadi MA, Nosratzehi S. Insulin resistance in patients with benign thyroid nodules. Arch Iran Med. 2015;18(9):572–576.
   PubMed Web of Science ®Google Scholar
• Murphy N, Carreras-Torres R, Song M, et al. Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and Mendelian randomization analyses. Gastroenterology. 2020;158(5):1300–12 e20. doi:10.1053/j.gastro.2019.12.020
   PubMed Web of Science ®Google Scholar
• Murphy N, Knuppel A, Papadimitriou N, et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with approximately 430 000 women. Ann Oncol. 2020;31(5):641–649. doi:10.1016/j.annonc.2020.01.066
   PubMed Web of Science ®Google Scholar
• Watts EL, Perez-Cornago A, Fensom GK, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int J Epidemiol. 2023;52(1):71–86. doi:10.1093/ije/dyac124
   PubMed Web of Science ®Google Scholar
• Zhang X, Sheng X, Miao T, Yao K, Yao D. Effect of insulin on thyroid cell proliferation, tumor cell migration, and potentially related mechanisms. Endocr Res. 2019;44(1–2):55–70. doi:10.1080/07435800.2018.1522641
   PubMed Web of Science ®Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159–169. doi:10.1038/nrc3215
   PubMed Web of Science ®Google Scholar
• Nozhat Z, Hedayati M. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. Mol Diagn Ther. 2016;20(1):13–26. doi:10.1007/s40291-015-0175-y
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Saeidi J, Azimi-Nejad M, Hashemy SI. Leptin-induced signaling pathways in cancer cell migration and invasion. Cell Oncol. 2019;42(3):243–260. doi:10.1007/s13402-019-00428-0
   Web of Science ®Google Scholar
• Mohammed Saeed W, Nasser Binjawhar D. Association of serum leptin and adiponectin concentrations with type 2 diabetes biomarkers and complications among Saudi women. Diabetes Metab Syndr Obes. 2023;16:2129–2140. doi:10.2147/DMSO.S405476
   PubMed Web of Science ®Google Scholar
• Revilla G, Corcoy R, Moral A, Escola-Gil JC, Mato E. Cross-talk between inflammatory mediators and the epithelial mesenchymal transition process in the development of thyroid carcinoma. Int J Mol Sci. 2019;20(10):2466. doi:10.3390/ijms20102466
   PubMed Web of Science ®Google Scholar
• Zhao J, Wen J, Wang S, Yao J, Liao L, Dong J. Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies. BMC Cancer. 2020;20(1):788. doi:10.1186/s12885-020-07299-x
   PubMed Web of Science ®Google Scholar
• Celano M, Maggisano V, Lepore SM, et al. Expression of leptin receptor and effects of leptin on papillary thyroid carcinoma cells. Int J Endocrinol. 2019;2019:5031696. doi:10.1155/2019/5031696
   PubMed Web of Science ®Google Scholar
• Nigro E, Orlandella FM, Polito R, et al. Adiponectin and leptin exert antagonizing effects on proliferation and motility of papillary thyroid cancer cell lines. J Physiol Biochem. 2021;77(2):237–248. doi:10.1007/s13105-021-00789-x
   PubMed Web of Science ®Google Scholar
• Xie SH, Rabbani S, Ness-Jensen E, Lagergren J. Circulating levels of inflammatory and metabolic biomarkers and risk of esophageal adenocarcinoma and Barrett esophagus: systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2109–2118. doi:10.1158/1055-9965.EPI-20-0572
   PubMed Web of Science ®Google Scholar
• Wang Y, Du L, Jing J, Zhao X, Wang X, Hou S. Leptin and leptin receptor expression as biomarkers for breast cancer: a retrospective study. BMC Cancer. 2023;23(1):260. doi:10.1186/s12885-023-10617-8
   PubMed Web of Science ®Google Scholar
• Vansaun MN, Cheng H-C, Chang T-K, Su W-C, Tsai H-L, Wang J-Y. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19(8):1926–1932. doi:10.1158/1078-0432.CCR-12-0930
   PubMed Web of Science ®Google Scholar
• Casado ME, Collado-Perez R, Frago LM, Barrios V. Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies. Int J Mol Sci. 2023;24(2):1422.
   PubMed Web of Science ®Google Scholar
• Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010;464(7293):1313–1319. doi:10.1038/nature08991
   PubMed Web of Science ®Google Scholar
• Bidulescu A, Dinh PC, Sarwary S, et al. Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study. BMC Endocr Disord. 2020;20(1):31. doi:10.1186/s12902-020-0511-z
   PubMed Web of Science ®Google Scholar
• Tsankof A, Tziomalos K. Adiponectin: a player in the pathogenesis of hormone-dependent cancers. Front Endocrinol. 2022;13:1018515. doi:10.3389/fendo.2022.1018515
   PubMed Web of Science ®Google Scholar
• Hopkins BD, Goncalves MD, Cantley LC. Obesity and cancer mechanisms: cancer metabolism. J Clin Oncol. 2016;34(35):4277–4283. doi:10.1200/JCO.2016.67.9712
   PubMed Web of Science ®Google Scholar
• Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep. 2019;8(4):413–433. doi:10.1007/s13679-019-00364-y
   PubMed Web of Science ®Google Scholar
• Tumminia A, Vinciguerra F, Parisi M, et al. Adipose tissue, obesity and adiponectin: role in endocrine cancer risk. Int J Mol Sci. 2019;20(12):2863. doi:10.3390/ijms20122863
   PubMed Web of Science ®Google Scholar
• Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer. 2018;142(7):1332–1342. doi:10.1002/ijc.31172
   PubMed Web of Science ®Google Scholar
• Maleki M, Karajibani M, Sarvani M, Montazerifar F, Salimi S, Heidari Z. Correlation between adiponectin rs2241766 and rs266729 polymorphisms and risk of papillary thyroid cancer. Mol Biol Res Commun. 2022;11(3):113–118. doi:10.22099/mbrc.2022.43012.1714
   PubMed Web of Science ®Google Scholar
• Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science. 2004;304(5674):1154–1158. doi:10.1126/science.1093466
   PubMed Web of Science ®Google Scholar
• Qiu L, Zhang GF, Yu L, Wang HY, Jia XJ, Wang TJ. Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition. Sci Rep. 2018;8(1):12522. doi:10.1038/s41598-018-30978-6
   PubMedGoogle Scholar
• Gao Y, Chen X, He Q, et al. Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. Proc Natl Acad Sci U S A. 2020;117(52):33295–33304. doi:10.1073/pnas.2005950117
   PubMed Web of Science ®Google Scholar
• Rosendahl AH, Bergqvist M, Lettiero B, Kimbung S, Borgquist S. Adipocytes and obesity-related conditions jointly promote breast cancer cell growth and motility: associations with CAP1 for prognosis. Front Endocrinol. 2018;9:689. doi:10.3389/fendo.2018.00689
   PubMed Web of Science ®Google Scholar
• Wang YY, Hung AC, Wu YC, et al. ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture model. Sci Rep. 2022;12(1):15437. doi:10.1038/s41598-022-19290-6
   PubMed Web of Science ®Google Scholar
• Cobbold C. Type 2 diabetes mellitus risk and exercise: is resistin involved? J Sports Med Phys Fitness. 2019;59(2):290–297. doi:10.23736/S0022-4707.18.08258-0
   PubMed Web of Science ®Google Scholar
• Peng X, Huang J, Zou H, et al. Roles of plasma leptin and resistin in novel subgroups of type 2 diabetes driven by cluster analysis. Lipids Health Dis. 2022;21(1):7. doi:10.1186/s12944-022-01623-z
   PubMed Web of Science ®Google Scholar
• Gong WJ, Liu JY, Yin JY, et al. Resistin facilitates metastasis of lung adenocarcinoma through the TLR4/Src/EGFR/PI3K/NF-kappaB pathway. Cancer Sci. 2018;109(8):2391–2400. doi:10.1111/cas.13704
   PubMed Web of Science ®Google Scholar
• Li B, Fang J, Zuo Z, et al. Activation of the porcine alveolar macrophages via toll-like receptor 4/NF-kappaB mediated pathway provides a mechanism of resistin leading to inflammation. Cytokine. 2018;110:357–366. doi:10.1016/j.cyto.2018.04.002
   PubMed Web of Science ®Google Scholar
• Zhang GQ, Jiao Q, Shen CT, et al. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. Cancer Sci. 2021;112(3):997–1010. doi:10.1111/cas.14752
   PubMed Web of Science ®Google Scholar
• Sudan SK, Deshmukh SK, Poosarla T, et al. Resistin: an inflammatory cytokine with multi-faceted roles in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188419. doi:10.1016/j.bbcan.2020.188419
   PubMed Web of Science ®Google Scholar
• Deshmukh SK, Srivastava SK, Bhardwaj A, et al. Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget. 2015;6(13):11231–11241. doi:10.18632/oncotarget.3591
   PubMedGoogle Scholar
• Dharshini LCP, Rasmi RR, Kathirvelan C, Kumar KM, Saradhadevi KM, Sakthivel KM. Regulatory components of oxidative stress and inflammation and their complex interplay in carcinogenesis. Appl Biochem Biotechnol. 2023;195(5):2893–2916. doi:10.1007/s12010-022-04266-z
   PubMed Web of Science ®Google Scholar
• Peng Y, Wang P, Gong J, et al. Association between the Finnish Diabetes Risk Score and cancer in middle-aged and older adults: involvement of inflammation. Metabolism. 2023;144:155586. doi:10.1016/j.metabol.2023.155586
   PubMed Web of Science ®Google Scholar
• Warakomski J, Romuk E, Jarzab B, Krajewska J, Sieminska L. Concentrations of selected adipokines, interleukin-6, and vitamin D in patients with papillary thyroid carcinoma in respect to thyroid cancer stages. Int J Endocrinol. 2018;2018:4921803. doi:10.1155/2018/4921803
   PubMed Web of Science ®Google Scholar
• Mauer J, Denson JL, Bruning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36(2):92–101. doi:10.1016/j.it.2014.12.008
   PubMed Web of Science ®Google Scholar
• Liang YN, Zhang Z, Song J, Yang F, Yang P, Wei X. Role of STAT3 expression in thyroid cancer: a meta-analysis and systematic review based on the Chinese Population. Evid Based Complement Alternat Med. 2022;2022:1116535. doi:10.1155/2022/1116535
   PubMed Web of Science ®Google Scholar
• Zhang GQ, Xi C, Shen CT, Song HJ, Luo QY, Qiu ZL. Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. Endocr Relat Cancer. 2023;30(9). doi:10.1530/ERC-23-0130
   Web of Science ®Google Scholar
• Liotti F, Collina F, Pone E, et al. Interleukin-8, but not the Related Chemokine CXCL1, sustains an autocrine circuit necessary for the properties and functions of thyroid cancer stem cells. Stem Cells. 2017;35(1):135–146. doi:10.1002/stem.2492
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 2009;373(9681):2088–2090. doi:10.1016/S0140-6736(09)61029-1
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–475. doi:10.2337/dc16-0985
   PubMed Web of Science ®Google Scholar
• Greco A, Coperchini F, Croce L, Magri F, Teliti M, Rotondi M. Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs. Front Pharmacol. 2023;14:1303844. doi:10.3389/fphar.2023.1303844
   PubMed Web of Science ®Google Scholar
• Glazer RI. PPARdelta as a metabolic initiator of mammary neoplasia and immune tolerance. PPAR Res. 2016;2016:3082340. doi:10.1155/2016/3082340
   PubMed Web of Science ®Google Scholar
• Lakshmi SP, Reddy AT, Banno A, Reddy RC. PPAR agonists for the prevention and treatment of lung cancer. PPAR Res. 2017;2017:8252796. doi:10.1155/2017/8252796
   PubMed Web of Science ®Google Scholar
• Lv S, Wang W, Wang H, Zhu Y, Lei C. PPARgamma activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer. 2019;19(1):204. doi:10.1186/s12885-019-5426-6
   PubMedGoogle Scholar
• Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid. 2009;19(9):953–956. doi:10.1089/thy.2008.0371
   PubMed Web of Science ®Google Scholar
• Tseng CH. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Ann Med. 2013;45(8):539–544. doi:10.3109/07853890.2013.851865
   PubMed Web of Science ®Google Scholar
• Chen JY, Wang JJ, Lee HC, Chi CW, Lee CH, Hsu YC. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells. J Chin Med Assoc. 2020;83(10):923–930. doi:10.1097/JCMA.0000000000000389
   PubMed Web of Science ®Google Scholar
• Jin JQ, Han JS, Ha J, Baek HS, Lim DJ. Lobeglitazone, a peroxisome proliferator-activated receptor-gamma agonist, inhibits papillary thyroid cancer cell migration and invasion by suppressing p38 MAPK signaling pathway. Endocrinol Metab. 2021;36(5):1095–1110. doi:10.3803/EnM.2021.1155
   Google Scholar
• Tsubaki M, Takeda T, Tomonari Y, et al. Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARgamma-independent pathway. J Cell Physiol. 2018;233(4):3638–3647. doi:10.1002/jcp.26225
   PubMed Web of Science ®Google Scholar
• Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I. Metformin as an anticancer agent. Trends Pharmacol Sci. 2018;39(10):867–878. doi:10.1016/j.tips.2018.07.006
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz M, Lobaton-Ginsberg M, Ferreira-Hermosillo A. Metformin in differentiated thyroid cancer: molecular pathways and its clinical implications. Biomolecules. 2022;12(4):574. doi:10.3390/biom12040574
   PubMed Web of Science ®Google Scholar
• He Y, Cao L, Wang L, Liu L, Huang Y, Gong X. Metformin inhibits proliferation of human thyroid cancer TPC-1 cells by decreasing LRP2 to suppress the JNK pathway. Onco Targets Ther. 2020;13:45–50. doi:10.2147/OTT.S227915
   PubMed Web of Science ®Google Scholar
• Ye J, Qi L, Chen K, et al. Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. Int J Oncol. 2019;55(1):331–339. doi:10.3892/ijo.2019.4820
   PubMed Web of Science ®Google Scholar
• Han B, Cui H, Kang L, et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway. Tumour Biol. 2015;36(8):6295–6304. doi:10.1007/s13277-015-3315-4
   PubMedGoogle Scholar
• Thakur S, Daley B, Klubo-Gwiezdzinska J. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol. 2019;63(2):R17–R35. doi:10.1530/JME-19-0083
   PubMed Web of Science ®Google Scholar
• Klubo-Gwiezdzinska J, Costello J, Patel A, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013;98(8):3269–3279. doi:10.1210/jc.2012-3799
   PubMed Web of Science ®Google Scholar
• Shin HS, Sun HJ, Whang YM, Park YJ, Park DJ, Cho SW. Metformin reduces thyroid cancer tumor growth in the metastatic niche of bone by inhibiting osteoblastic RANKL productions. Thyroid. 2021;31(5):760–771. doi:10.1089/thy.2019.0851
   PubMed Web of Science ®Google Scholar
• Cho YY, Kang MJ, Kim SK, et al. Protective effect of metformin against thyroid cancer development: a population-based study in Korea. Thyroid. 2018;28(7):864–870. doi:10.1089/thy.2017.0550
   PubMed Web of Science ®Google Scholar
• Mushtaq A, Azam U, Mehreen S, Naseer MM. Synthetic alpha-glucosidase inhibitors as promising anti-diabetic agents: recent developments and future challenges. Eur J Med Chem. 2023;249:115119. doi:10.1016/j.ejmech.2023.115119
   PubMed Web of Science ®Google Scholar
• Zhan ZT, Liu L, Cheng MZ, Gao Y, Zhou WJ, Xu B. The effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment. J Immunol Res. 2022;2022:2651790. doi:10.1155/2022/2651790
   PubMed Web of Science ®Google Scholar
• Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer. 2012;13(2):143–148. doi:10.1016/j.cllc.2011.10.002
   PubMed Web of Science ®Google Scholar
• Tseng YH, Tsan YT, Chan WC, Sheu WH, Chen PC. Use of an alpha-glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based cohort study. Diabetes Care. 2015;38(11):2068–2074. doi:10.2337/dc15-0563
   PubMed Web of Science ®Google Scholar
• Li C, Kuang J, Zhao Y, Sun H, Guan H. Effect of type 2 diabetes and antihyperglycemic drug therapy on signs of tumor invasion in papillary thyroid cancer. Endocrine. 2020;69(1):92–99. doi:10.1007/s12020-020-02291-8
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Z, Khan BA, Hou K. Editorial: role of gut microbiota in diabetes mellitus and tumor immunity. Front Immunol. 2023;14:1185080. doi:10.3389/fimmu.2023.1185080
   PubMed Web of Science ®Google Scholar